Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Distinctive 'qualifier' for all biologics could solve biosimilar INN dispute

This article was originally published in SRA

Executive Summary

A compromise proposal being discussed this week by the World Health Organization's expert group on international non-proprietary names (INNs) could help to settle the dispute between originator and biosimilar companies as to whether biosimilars should have a distinguishable INN from that of their reference product.

You may also be interested in...



French HTA Body Backs Routine Six-Week Interval In COVID-19 Vaccine Dosing

France's health technology assessment body says that delaying by six weeks the second dose of the two mRNA vaccines approved for use against COVID-19 would allow at least 700,000 more people to receive their jab in the first month.

Coronavirus Notebook: EU Publishes CureVac Vaccine Contract, AZ and Pfizer Under Attack Over Supply Cuts

The European Ombudsman has opened an inquiry regarding the disclosure of vaccine contracts with other companies, and the European Commission is planning a “sharing mechanism” for vaccines bought by EU member states.

Pfizer/BioNTech’s COVID-19 Vaccine First To Be Approved In Australia

Australia will begin its coronavirus vaccination program with Comirnaty. The Oxford University/AstraZeneca vaccine is expected to be the next to receive approval.

UsernamePublicRestriction

Register

LL1135544

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel